02/03/2015 14:02:17 Free Membership Login

Mylan N.V. News (NASDAQ:MYL)

DateTimeSource
Headline
03/02/20159:31AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Falter Ahead Of Data Deluge
By Anora Mahmudova and Sara Sjolin, MarketWatch Lumber Liquidators tumbles after '60 Minutes' report NEW YORK (MarketWatch) -- U.S. stock futures struggled to hold on to modest gains ahead of the opening bell, as investors assessed personal-income data and waited for a raft of economic reports that should provide insight... More...>>
03/02/20157:53AMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Edge Higher Ahead Of Data Deluge
By Sara Sjolin, MarketWatch Berkshire Hathaway slips after earnings LONDON (MarketWatch) -- U.S. stock investors were hoping to kick off March on an upbeat note on Monday, with futures edging higher ahead of a raft of economic reports -- including consumer spending and manufacturing numbers -- that will offer signs about... More...>>
03/01/20155:35PMSEEKNotable earnings after Monday’s close
http://seekingalpha.com/news/2336006-notable-earnings-after-monday-s-close?source=partner_advfn More...>>
03/01/20156:18AMDJNMARKET SNAPSHOT: Jobs Report Key For Investors In Week Ahead
By Wallace Witkowski, MarketWatch Devil is in details of jobs report to push Fed to raise rates SAN FRANCISCO (MarketWatch) -- Investor attention turns to the latest jobs report this week along with a slew of other economic data. Stocks were roughly flat last week but finished the month up with hefty gains (http://www.marketwatch.com/story/us-stocks-wall-street-waits-for-gdp-sentiment-and-more-fed-speakers-2015-02-27... More...>>
02/27/201512:30PMPRNUSMylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business
Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business PR Newswire POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015 POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015 /PRNewswire/ -- Mylan N.V. and Mylan Inc. (Nasdaq: MYL) today announced the successful completion of... More...>>
02/23/201512:18PMSEEKMylan named Gilead's exclusive distributor of branded HCV meds in India
http://seekingalpha.com/news/2317116-mylan-named-gileads-exclusive-distributor-of-branded-hcv-meds-in-india?source=partner_advfn More...>>
02/23/201510:45AMPRNUSMylan Specialty to Present Findings from EpiPen4Schools® Program Survey
Mylan Specialty to Present Findings from EpiPen4Schools® Program Survey Data from an assessment of more than 6,000 schools provide information about anaphylaxis triggers, response and education in the school setting PR Newswire PITTSBURGH, Feb. 23, 2015 PITTSBURGH, Feb. 23, 2015 /PRNewswire/ -- Mylan Specialty, the full... More...>>
02/23/20157:00AMPRNUSMylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India
Mylan Signs Exclusive Agreement with Gilead Sciences to Distribute Sovaldi® and Harvoni® in India PR Newswire PITTSBURGH and HYDERABAD, India, Feb. 23, 2015 PITTSBURGH and HYDERABAD, India, Feb. 23, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its Indian subsidiary, Mylan Pharmaceuticals Private... More...>>
02/22/20155:20PMDJNValeant Pharmaceuticals to Buy Salix for About $10 Billion -- 2nd Update
By Jonathan D. Rockoff and Liz Hoffman Valeant Pharmaceuticals International Inc. said Sunday it would buy Salix Pharmaceuticals Ltd. for about $10 billion, a return to its big deal-making ways after a failed bid for Botox maker Allergan Inc. last year. Quebec-based Valeant said it would pay $158 a share in cash for Salix... More...>>
02/22/20155:05PMDJNValeant Pharmaceuticals to Buy Salix for About $10 Billion -- Update
By Jonathan D. Rockoff and Liz Hoffman Valeant Pharmaceuticals International Inc. said Sunday it would buy Salix Pharmaceuticals Ltd. for about $10 billion, a return to its big deal-making ways after a failed bid for Botox maker Allergan Inc. last year. Quebec-based Valeant said it would pay $158 a share in cash for Salix... More...>>
02/09/201511:45AMPRNUSMylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast
Mylan Schedules Fourth Quarter and Year End 2014 Financial Results Conference Call and Live Webcast PR Newswire PITTSBURGH, Feb. 9, 2015 PITTSBURGH, Feb. 9, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast, including a slide presentation, on Monday, March... More...>>
02/09/201511:00AMPRNUSMylan Confirms First-to-File Patent Challenge Relating to NEXAVAR®
Mylan Confirms First-to-File Patent Challenge Relating to NEXAVAR® - Expects to be eligible for 180 days of marketing exclusivity - PR Newswire PITTSBURGH, Feb. 9, 2015 PITTSBURGH, Feb. 9, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its subsidiary Mylan Pharmaceuticals have been sued by... More...>>
02/02/20152:55PMDJNMylan to Buy Businesses From Famy Care for $750 Million
By Chelsey Dulaney Mylan Inc. has agreed to buy certain women's health-care businesses from India's Famy Care Ltd. for $750 million in cash, in a move that will position Mylan as a leading provider of contraceptives in emerging markets. Mylan has partnered with Famy in developed markets including North America, Europe... More...>>
02/02/20157:00AMPRNUSTheravance Biopharma, Inc. and Mylan Partner to Develop and Commercialize a Novel LAMA Compound, TD-4208, for COPD
Theravance Biopharma, Inc. and Mylan Partner to Develop and Commercialize a Novel LAMA Compound, TD-4208, for COPD Phase 3 registrational studies of TD-4208 are anticipated to begin in 2015 PR Newswire GEORGE TOWN, Grand Cayman and PITTSBURGH, Feb. 2, 2015 GEORGE TOWN, Grand Cayman and PITTSBURGH, Feb. 2, 2015 /PRNewswire/... More...>>
02/02/20156:44AMPRNUSMylan to Acquire Famy Care Businesses to Create a Leading Women's Health Care Franchise
Mylan to Acquire Famy Care Businesses to Create a Leading Women's Health Care Franchise Expected to be immediately accretive to Mylan's adjusted diluted earnings per share upon closing PR Newswire PITTSBURGH and MUMBAI, India, Feb. 2, 2015 PITTSBURGH and MUMBAI, India, Feb. 2, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq:... More...>>
01/29/201511:18AMPRNUSMylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty...
Mylan Shareholders Overwhelmingly Approve Agreement Implementing Acquisition of Abbott's Non-U.S. Developed Markets Specialty and Branded Generics Business PR Newswire PITTSBURGH, Jan. 29, 2015 PITTSBURGH, Jan. 29, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced that at a Special Meeting of Shareholders held Jan... More...>>
01/29/20159:04AMDJNAbbott Laboratories Profit Grows 54%
By Tess Stynes Abbott Laboratories said its fourth-quarter earnings soared as the company posted stronger revenue in its nutrition and diagnostics businesses, although currency fluctuations weighed on sales growth. Abbott has been realigning its business in a series of deals. Last year Abbott reached an agreement to shed... More...>>
01/26/201510:58AMPRNUSMylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent
Mylan Expands Hepatitis C Licensing Agreement with Gilead to Include Investigational Pan-Genotypic Agent PR Newswire PITTSBURGH and HYDERABAD, India, Jan. 26, 2015 PITTSBURGH and HYDERABAD, India, Jan. 26, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited is expanding... More...>>
01/20/20155:13PMDJNSupreme Court Sides With Teva in Patent Case on Copaxone -- 2nd Update
By Brent Kendall And Ashby Jones The U.S. Supreme Court on Tuesday reversed an appeals court ruling that invalidated a Teva Pharmaceutical Industries Ltd. patent on the blockbuster multiple-sclerosis drug Copaxone, giving the drug maker a new opportunity to forestall generic competition. The ruling breathes new life into... More...>>
01/20/20153:29PMDJNSupreme Court Sides With Teva in Patent Case on Copaxone -- 2nd Update
By Brent Kendall And Ashby Jones The U.S. Supreme Court on Tuesday reversed an appeals court ruling that invalidated a Teva Pharmaceutical Industries Ltd. patent on the blockbuster multiple-sclerosis drug Copaxone, giving the drug maker a new opportunity to forestall generic competition. The ruling breathes new life into... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq myl150302 14:02